Last reviewed · How we verify
Ezalutamide
Ezalutamide, developed by Sanofi, has been discontinued and its intended indication is not specified. The discontinuation of this drug suggests that it did not meet the necessary safety or efficacy standards during its development. As a result, Ezalutamide will not be available as a treatment option for any medical conditions.
At a glance
| Generic name | Ezalutamide |
|---|---|
| Also known as | Xtandi |
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalut (Phase 2)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ezalutamide CI brief — competitive landscape report
- Ezalutamide updates RSS · CI watch RSS
- Sanofi portfolio CI